LifeSci Advisors Initiates Coverage of Receptos Inc
03 September 2013 - 10:00PM
Marketwired
- Phase II Program in Multiple Sclerosis and
Inflammatory Bowel Disease
- Topline Data Expected in Mid-2014
- Available for Download at
http://www.lifesciadvisors.com/clients/receptos/
LifeSci Advisors, LLC, a leading provider of investment research
and investor relations services in the life sciences sector, today
announced that it has initiated coverage of Receptos Inc. (NASDAQ:
RCPT), a biopharmaceutical company developing treatments for immune
diseases. Receptos is conducting Phase II clinical trials with lead
candidate RPC1063 in multiple sclerosis (MS) and inflammatory bowel
disease (IBD) patients, two markets that exceed $15 billion, and
topline results are expected in mid-2014. RPC1063 is an oral S1PR
modulator with several distinct potential advantages over existing
S1PR modulators, such as Gilenya®, and has an improved safety
profile while maintaining strong immunomodulation properties.
"Today's MS market is incredibly dynamic as patients cycle
between therapies to seek relief from relapses and to limit
treatment-related side effects," said Andrew I. McDonald, Ph.D.,
Founding Partner at LifeSci Advisors. "As oral drugs begin to
emerge and become the preferred treatment option, RPC1063 has the
potential to tap into a significant portion of the market."
Receptos has significantly de-risked the RPC1063 program by
developing a drug with superior safety and pharmacokinetic
properties to other S1PR modulators either on the market or in
development. The validation of this drug class through the approval
of Gilenya® makes the path to market clear and feasible. Targeting
patients with IBD, in addition to MS, gives Receptos access to a
set of patients that have few viable treatment options. Receptos
has a balanced portfolio of drug candidates, including two
preclinical programs, setting the stage for continued milestones
over the next several years.
In a 54 page Initiation Report by LifeSci Advisors, we explain
the development path going forward for Receptos' programs. The
report discusses the competitive advantages of RPC1063 over other
S1PR modulators and how these advantages position the drug within
the marketplace. We highlight the dynamic nature of the multiple
sclerosis market and the strong potential for oral treatments in
the future. We also discuss the application of RPC1063 in patients
with inflammatory bowel disease, and the strong preclinical
programs in development by Receptos.
Dr. McDonald's full Initiation Report is available to download
at no cost at the LifeSci Advisors website,
www.lifesciadvisors.com. In addition to this Initiation Report,
LifeSci Advisors will also provide ongoing coverage and event-based
research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I.
McDonald, an industry veteran with more than 15 years of healthcare
industry experience. Prior to co-founding LSA, Dr. McDonald was the
Senior Biotechnology Analyst at Great Point Partners, a leading
health care investment firm with over $500 million under
management. Before Great Point, he was Co-Head of Healthcare
Research and Lead Biotechnology Analyst at ThinkEquity Partners, a
boutique investment banking firm focused on growth companies. Dr.
McDonald holds a Ph.D. in organic chemistry from the University of
California, Irvine, and, earlier in his career, worked as a
medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and
communications consultancy dedicated to the life sciences industry.
The firm provides strategic counsel, customized marketing
communications, comprehensive research reports and investor
relations services to companies that specialize in the discovery,
development and commercialization of drugs, drug delivery systems,
medical devices and diagnostics. To learn more about LSA, visit the
company's website, www.lifesciadvisors.com.
Important Disclosures:
The research report described in this press release is not
intended as an offering, recommendation, or a solicitation of an
offer to buy or sell securities. The securities discussed in LSA
research reports may be unsuitable for some investors depending on
their specific investment objectives, financial status, risk
profile, or particular needs. Investors should consider LSA reports
as only a single factor in making their investment decisions and
should not rely solely on these reports in evaluating whether or
not to buy or sell the securities of the subject company. LifeSci
Advisors has been compensated by the company that is the subject of
the report described and future research reports, investor
relations services, and general consulting services. Please read
each report's full disclosures and analyst background on the LSA
website, www.lifesciadvisors.com, before investing. LifeSci
Advisors is not a registered investment adviser or
broker-dealer.
Forward-looking statements:
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. These forward-looking
statements represent LSA's judgment as of the date of this release.
LifeSci Advisors disclaims, however, any intent or obligation to
update these forward-looking statements.
Media Contact: Michael Rice Phone: (646) 597-6979 Email:
mrice@lifesciadvisors.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024